Churchill Capital Corp XI - Class A Ordinary Shares (NQ:CCXI)

10.36 -0.00 (-0.05%)

Delayed Quote Updated: 4:00 PM EDT, Oct 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Churchill Capital Corp XI - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

ChemoCentryx's Return On Capital Employed Insights ↗

September 01, 2022

According to data from Benzinga Pro, during Q2, ChemoCentryx's (NASDAQ:CCXI) reported sales totaled $11.76 million. Despite a 18.02% increase in earnings, the company posted a loss of $31.65 million.

Via Benzinga

INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CCXI

August 30, 2022

From Scott+Scott Attorneys at Law LLP

Via Business Wire

10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others ↗

August 29, 2022

These names are benefitting from M&A, clinical data and promising regulatory actions.

Via Investor's Business Daily

Whither Small Caps After Fed’s Tough Talk? ↗

August 29, 2022

For now its better not to “Fight the Fed” because they are fighting the with the market. Now that everyone is scared of the Fed's rhetoric it would be better to wait a week or so as more data and...

Via Talk Markets

ChemoCentryx: Q2 Earnings Insights ↗

August 09, 2022

ChemoCentryx (NASDAQ:CCXI) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Via Benzinga

3 Analysts Have This to Say About ChemoCentryx ↗

August 05, 2022

ChemoCentryx (NASDAQ:CCXI) has observed the following analyst ratings within the last quarter:

Via Benzinga

ChemoCentryx Stock More Than Doubles On $4B Buyout ↗

August 04, 2022

Via Benzinga

Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million ↗

August 23, 2022

The biopharma buying spree continued Tuesday with glaucoma drugs maker Aerie.

Via Investor's Business Daily

Check your Portfolio for Small Cap Weighting: Growth, Innovation or Speculation? ↗

August 15, 2022

The SPDR S&P Biotech ETF remains our key indicator for small cap biotechs. It is up 14.55% over one month at $93.78 but is still down 16% YTD. The Russell 2000 is up 16.5% over one month mirroring...

Via Talk Markets

Why Jim Cramer Says This Financial Stock Is 'Terrific' ↗

August 12, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said The Charles Schwab Corporation (NYSE: SCHW) is "terrific."

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022 ↗

August 10, 2022

Via Benzinga

Earnings Preview: ChemoCentryx ↗

August 08, 2022

ChemoCentryx (NASDAQ:CCXI) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. Analysts estimate that ChemoCentryx...

Via Benzinga

Small Cap Biotechs Perk Up On Dealmaking ↗

August 06, 2022

With M&A picking up we would think smaller deals make sense for large cap biopharma to expand pipelines and complement technology.

Via Talk Markets

Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review ↗

August 05, 2022

The Nasdaq and small caps rose while the S&P 500 is hitting resistance.

Via Investor's Business Daily

Where ChemoCentryx Stands With Analysts ↗

August 05, 2022

Over the past 3 months, 4 analysts have published their opinion on ChemoCentryx (NASDAQ:CCXI) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022 ↗

August 05, 2022

Upgrades

Via Benzinga

Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday ↗

August 05, 2022

U.S. stocks closed mixed on Thursday following the release of weekly jobless claims data. Here is the list of some big stocks moving higher in the previous session.

Via Benzinga

Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday ↗

August 05, 2022

Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per share...

Via Benzinga

Amgen Narrows Sales Outlook Following Plans To Acquire ChemoCentryx ↗

August 04, 2022

The company also reported a second-quarter beat and reiterated its earnings outlook.

Via Investor's Business Daily

Gold Tops 1,800; Alibaba Reports Upbeat Results ↗

August 04, 2022

U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping around 75 points on Thursday

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

August 04, 2022

Via Benzinga

ChemoCentryx Shares Are Jumping 110% Thursday: Here's Why ↗

August 04, 2022

Shares of ChemoCentryx, Inc. (NASDAQ: CCXI) are skyrocketing Thursday following a groundbreaking announcement for the biopharmaceutical company. Why Is It Moving?

Via Benzinga

Nasdaq Edges Higher; Crude Oil Falls Sharply ↗

August 04, 2022

U.S. stocks pared some losses midway through trading, with the Nasdaq Composite turning higher on Thursday.

Via Benzinga

Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session ↗

August 04, 2022

Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday.

Via Benzinga

Why Is Nikola (NKLA) Stock Up Today? ↗

August 04, 2022

Nikola (NKLA) stock is climbing higher on Thursday thanks to the release of its earnings report for Q2 2022 and other news.

Via InvestorPlace

ChemoCentryx (NASDAQ: CCXI) to be Acquired by Amgen (NASDAQ: AMGN) for $3.7 Billion in Cash

August 04, 2022

ChemoCentryx, Inc. (NASDAQ: CCXI) is engaged as a biopharmaceutical company that is focused on the research, development and commercialization of

Via Spotlight Growth

ChemoCentryx (CCXI) Stock Soars 100% on Amgen Acquisition ↗

August 04, 2022

ChemoCentryx (CCXI) stock is rocketing higher on Thursday as investors react to news of an acquisition deal with Amgen (AMGN).

Via InvestorPlace

Amgen Plans $3.7 Billion ChemoCentryx Buyout, Tapping Into A New Market ↗

August 04, 2022

The company will pay $52 per share to buy ChemoCentryx, a rare disease-focused firm.

Via Investor's Business Daily

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗

August 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

CCXI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of ChemoCentryx, Inc. Is Fair to Shareholders

August 04, 2022

From Halper Sadeh LLP

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.